ALSO NOTED: Pharma plant explosions in India, Ireland; Sanofi inks $192M avian flu vaccine deal;

> At least one worker was killed and others seriously injured in two separate pharmaceutical-plant explosions, one at Sirius India Ltd. in Hyderabad, India, and the other at Cordon PharmaChem in Little Island, Ireland. Report | Report

> Sanofi Pasteur announced a $192.5 million contract to provide 38.5 million doses of avian influenza vaccine to the U.S. government. Report

> Australia's drug watchdogs have received a petition to change the Roche antiviral Tamiflu to an over-the-counter drug so that patients can get it quickly enough to be effective. Report

> India's Lupin launched its urinary tract infection treatment Suprax in the U.S. Report

> Bayer got European approval to market its Zevalin lymphoma treatment as an add-on to first-line chemo; previously the drug was only approved as a second-line treatment. Report

> Apotex is suing the FDA for 156 more days of exclusivity on generic Plavix; the company launched its copycat version at risk in 2006, but was stopped by a preliminary injunction 23 days later. Report

> Glenmark Pharma posted fourth-quarter profits of 2.19 billion rupees, triple the same period a year ago. Report

> There's a big sigh of relief coming from Wyeth and Progenics as the FDA approved Relistor, a subcutaneous injection for opioid-induced constipation in patients with advanced illness who are receiving palliative care. Report

> Solvay has made a $278.2 million (€177.6 million) takeover bid for Belgium's Innogenetics. Report

> Another day, another big biotech deal. This time it's Japan's Astellas Pharma, which is paying $760 million for access to CoMentis's Alzheimer's drug. Report

> Which Massachusetts-based biotechs are ripe for buyouts. Report

And Finally... Would patients be better off if doctors stopped accepting insurance? Report

Suggested Articles

More than a year after J&J and Bayer pulled the plug on Xarelto in patients after a rare valve replacement, the pair are still seeking answers.

Novartis hopes to leverage its existing presence in the hematology community to achieve a successful launch of Adakveo.

AstraZeneca's Farxiga is touting its heart failure data in patients with or without diabetes, but results in non-diabetics looks particularly strong.